Methionine aminopeptidase-2 inhibitors and methods of use thereof

Abstract

The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.

1 . A compound of Formula I, 
       
         
           
           
               
               
           
         
       
       wherein
 A is a Met-AP2 inhibitory core; 
 W is O or NR 2 ; 
 R 1  and R 2  are each, independently, hydrogen or alkyl; 
 X is alkylene or substituted alkylene; 
 n is 0 or 1; 
 R 3  and R 4  are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R 3  and R 4 , together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or R 3  and R 4  together form an alkylene group; 
 Z is —C(O)— or alkylene-C(O)—; and 
 P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group OR 5  or N(R 6 )R 7 , wherein
 R 5 , R 6  and R 7  are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or R 6  and R 7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring structure; 
 
 or 
 Z is —O—, —NR 8 —, alkylene-O— or alkylene-NR 8 —, where R 8  is hydrogen or alkyl; and 
 P is hydrogen, alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z. 
 
     
     
         2 . The compound of  claim 1 , wherein at least one of R 1 , R 3  and R 4  is a substituted or unsubstituted alkyl group. 
     
     
         3 . The compound of  claim 2 , wherein at least one of R 1 , R 3  and R 4  is a substituted or unsubstituted normal, branched or cyclic C 1 -C 6  alkyl group. 
     
     
         4 . The compound of  claim 3 , wherein at least one of R 1 , R 3  and R 4  is a normal or branched C 1 -C 4  alkyl group. 
     
     
         5 . The compound of  claim 1 , wherein one of R 3  and R 4  is a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted heteroarylalkyl group, or a substituted or unsubstituted aryl alkyl group. 
     
     
         6 . The compound of  claim 5 , wherein one of R 3  and R 4  is selected from the group consisting of phenyl, naphthyl, indolyl, imidazolyl, pyridyl, benzyl, naphthylmethyl, indolylmethyl, imidazolylmethyl and pyridylmethyl. 
     
     
         7 . The compound of  claim 1 , wherein n is 1 and X is C 1 -C 6 -alkylene. 
     
     
         8 . The compound of  claim 7 , wherein X is methylene or ethylene. 
     
     
         9 . The compound of  claim 1 , wherein Z is C 1 -C 6 -alkylene-C(O)—. 
     
     
         10 . The compound of  claim 9 , wherein Z is methylene-C(O)— or ethylene-C(O)—. 
     
     
         11 . The compound of  claim 1 , wherein at least one of R 6  and R 7  is alkyl, substituted alkyl, substituted or unsubstituted azacycloalkyl or substituted or unsubstituted azacycloalkylalkyl. 
     
     
         12 . The compound of  claim 11 , wherein at least one of R 6  and R 7  is an azacycloalkyl group having an N-alkyl substituent. 
     
     
         13 . The compound of  claim 12 , wherein the N-alkyl substituent is a C 1 -C 4 -alkyl group. 
     
     
         14 . The compound of  claim 13 , wherein the N-alkyl substituent is a methyl group. 
     
     
         15 . The compound of  claim 1 , wherein R 6  and R 7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted five or six-membered aza- or diazacycloalkyl group. 
     
     
         16 . The compound of  claim 15 , wherein R 6  and R 7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted five or six-membered diazacycloalkyl group which includes an N-alkyl substituent. 
     
     
         17 . The compound of  claim 16 , wherein the N-alkyl substituent is a C 1 -C 4 -alkyl group. 
     
     
         18 . The compound of  claim 17 , wherein the N-alkyl substituent is a methyl group. 
     
     
         19 . The compound of  claim 1 , wherein P is NH 2  or one of the groups shown below: 
       
         
           
           
               
               
           
         
       
     
     
         20 . A compound of Formula XV, 
       
         
           
           
               
               
           
         
       
       wherein
 A is a MetAP-2 inhibitory core; 
 W is O or NR; 
 each R is, independently, hydrogen or alkyl; 
 Z is —C(O)— or -alkylene-C(O)—; 
 P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is —OR, Q is not hydrogen; 
 or 
 Z is -alkylene-O— or -alkylene-N(R)—; 
 P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen; 
 and pharmaceutically acceptable salts thereof. 
 
     
     
         21 . The compound of  claim 20 , wherein Z is —C(O)— or C 1 -C 4 -alkylene-C(O)—. 
     
     
         22 . The compound of  claim 21 , wherein Z is —C(O)— or C 1 -C 2 -alkylene-C(O)—. 
     
     
         23 . The compound of  claim 21 , wherein Q is linear, branched or cyclic C 1 -C 6 -alkyl, phenyl or naphthyl. 
     
     
         24 . The compound of  claim 23 , wherein Q is isopropyl, phenyl or cyclohexyl. 
     
     
         25 . The compound of  claim 1 , wherein Z is C 1 -C 6 -alkylene-O— or C 1 -C 6 -alkylene-NR—. 
     
     
         26 . The compound of  claim 25 , wherein Z is C 1 -C 4 -alkylene-O— or C 1 -C 4 -alkylene-NH—. 
     
     
         27 . The compound of  claim 26 , wherein Z is C 1 -C 2 -alkylene-O— or C 1 -C 2 -alkylene-NH. 
     
     
         28 . The compound of  claim 25 , wherein Q is linear, branched or cyclic C 1 -C 6 -alkyl, phenyl or naphthyl. 
     
     
         29 . The compound of  claim 28 , wherein Q is isopropyl, phenyl or cyclohexyl. 
     
     
         30 . The compound of  claim 20 , wherein each R is, independently, hydrogen or linear, branched or cyclic C 1 -C 6 -alkyl. 
     
     
         31 . The compound of  claim 30 , wherein each R is, independently, hydrogen or linear or branched C 1 -C 4 -alkyl. 
     
     
         32 . The compound of  claim 31 , wherein each R is, independently, hydrogen or methyl. 
     
     
         33 . The compound of  claim 32 , wherein each R is hydrogen. 
     
     
         34 . The compound of  claim 20 , wherein A is of Formula II, 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  is hydrogen or alkoxy; 
 R 2  is hydrogen or hydroxy; 
 R 3  is hydrogen or alkyl; and 
 D is linear or branched alkyl or arylalkyl: or D is of the structure 
 
       
         
           
           
               
               
           
         
       
     
     
         35 . The compound of  claim 34 , wherein R 1  is C 1 -C 4 -alkoxy. 
     
     
         36 . The compound of  claim 35 , wherein R 1  is methoxy. 
     
     
         37 . The compound of  claim 34 , wherein R 3  is hydrogen or C 1 -C 4 -alkyl. 
     
     
         38 . The compound of  claim 37 , wherein R 3  is methyl. 
     
     
         39 . The compound of  claim 34 , wherein D is linear, branched or cyclic C 1 -C 6 -alkyl; or aryl-C 1 -C 4 -alkyl. 
     
     
         40 . The compound of  claim 20 , wherein A is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       wherein
 p is an integer from 0 to 10; 
 R 1  is hydrogen, —OH or C 1 -C 4 -alkoxy; 
 X is a leaving group; and 
 R 2  is H, OH, amino, C 1 -C 4 -alkylamino or di(C 1 -C 4 -alkyl)amino. 
 
     
     
         41 . The compound of  claim 40 , wherein A is of the formula 
       
         
           
           
               
               
           
         
       
     
     
         42 . The compound of  claim 20 , wherein P comprises from 1 to about 20 amino acid residues. 
     
     
         43 . The compound of  claim 42 , wherein P comprises an amino acid sequence which is a substrate for a matrix metalloprotease. 
     
     
         44 . The compound of  claim 43 , wherein the matrix metalloprotease is selected from the group consisting of MMP-2, MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13 and MMP-26. 
     
     
         45 . The compound of  claim 44 , wherein the matrix metalloprotease is MMP-2 or MMP-9. 
     
     
         46 . The compound of  claim 45 , wherein P comprises the sequence -Pro-Leu-Gly-Xaa-, wherein Xaa is a naturally occurring amino acid residue. 
     
     
         47 . The compound of  claim 46 , wherein P comprises a sequence selected from the group consisting of Pro-Cha-Gly-Cys(Me)-His (SEQ ID NO:2); Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg (SEQ ID NO:3); Pro-Gln-Gly-Ile-Ala-Gly-Trp (SEQ ID NO:4); Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg (SEQ ID NO:5); Pro-Leu-Gly-Met-Trp-Ser-Arg (SEQ ID NO:35); Pro-Leu-Gly-Leu-Trp-Ala-D-Arg (SEQ ID NO:6); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:7); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:8); Pro-Leu-Ala-Tyr-Trp-Ala-Arg (SEQ ID NO:9); Pro-Tyr-Ala-Tyr-Trp-Met-Arg (SEQ ID NO:10); Pro-Cha-Gly-Nva-His-Ala (SEQ ID NO: 11); Pro-Leu-Ala-Nva (SEQ ID NO: 12); Pro-Leu-Gly-Leu (SEQ ID NO: 13); Pro-Leu-Gly-Ala (SEQ ID NO: 14); Arg-Pro-Leu-Ala-Leu-Trp-Arg-Ser (SEQ ID NO: 15); Pro-Cha-Ala-Abu-Cys(Me)-His-Ala (SEQ ID NO: 16); Pro-Cha-Ala-Gly-Cys(Me)-His-Ala (SEQ ID NO: 17); Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu (SEQ ID NO:18); Pro-Lys-Pro-Leu-Ala-Leu (SEQ ID NO:19); Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met (SEQ ID NO:20); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:21); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:22); and Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp (SEQ ID NO:23). 
     
     
         48 . A compound of the formula 
       
         
           
           
               
               
           
         
       
       wherein
 W is O or NR; 
 each R is, independently hydrogen or a C 1 -C 4 -alkyl; 
 Q is hydrogen; linear, branched or cyclic C 1 -C 6 -alkyl; or aryl; 
 R 1  is hydroxy, C 1 -C 4 -alkoxy or halogen; 
 Z is —C(O)— or C 1 -C 4 -alkylene; 
 P is NHR, OR, or a peptide comprising 1 to 100 amino acid residues attached to Z at the N-terminus; or 
 Z is alkylene-O or alkylene-NR; and 
 P is hydrogen or peptide comprising 1 to 100 amino acid residues attached to Z at the C-terminus; 
 or a pharmaceutically acceptable salt thereof; provided that when P is hydrogen, NHR or OR, Q is not hydrogen. 
 
     
     
         49 . The compound of  claim 48 , wherein
 W is O or NH;   Z is alkylene-O or alkylene-NH;   Q is isopropyl;   R 1  is methoxy; and   P comprises from 1 to 15 amino acid residues.   
     
     
         50 . The compound of  claim 49 , wherein
 W is O; and   P comprises 10 or fewer amino acid residues.   
     
     
         51 . The compound of  claim 48 , wherein P comprises from 1 to about 20 amino acid residues. 
     
     
         52 . The compound of  claim 51 , wherein P comprises an amino acid sequence which is a substrate for a matrix metalloprotease. 
     
     
         53 . The compound of  claim 52 , wherein the matrix metalloprotease is selected from the group consisting of MMP-2, MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13 and MMP-26. 
     
     
         54 . The compound of  claim 53 , wherein the matrix metalloprotease is MMP-2 or MMP-9. 
     
     
         55 . The compound of  claim 54 , wherein P comprises the sequence -Pro-Leu-Gly-Xaa-, wherein Xaa is a naturally occurring amino acid residue. 
     
     
         56 . The compound of  claim 55 , wherein P comprises a sequence selected from the group consisting of Pro-Cha-Gly-Cys(Me)-His (SEQ ID NO:2); Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg (SEQ ID NO:3); Pro-Gln-Gly-Ile-Ala-Gly-Trp (SEQ ID NO:4); Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg (SEQ ID NO:5); Pro-Leu-Gly-Met-Trp-Ser-Arg (SEQ ID NO:35); Pro-Leu-Gly-Leu-Trp-Ala-D-Arg (SEQ ID NO:6); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:7); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:8); Pro-Leu-Ala-Tyr-Trp-Ala-Arg (SEQ ID NO:9); Pro-Tyr-Ala-Tyr-Trp-Met-Arg (SEQ ID NO:10); Pro-Cha-Gly-Nva-His-Ala (SEQ ID NO: 11); Pro-Leu-Ala-Nva (SEQ ID NO: 12); Pro-Leu-Gly-Leu (SEQ ID NO:13); Pro-Leu-Gly-Ala (SEQ ID NO:14); Arg-Pro-Leu-Ala-Leu-Trp-Arg-Ser (SEQ ID NO: 15); Pro-Cha-Ala-Abu-Cys(Me)-His-Ala (SEQ ID NO: 16); Pro-Cha-Ala-Gly-Cys(Me)-His-Ala (SEQ ID NO: 17); Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu (SEQ ID NO:18); Pro-Lys-Pro-Leu-Ala-Leu (SEQ ID NO:19); Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met (SEQ ID NO:20); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:21); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:22); and Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp (SEQ ID NO:23). 
     
     
         57 . An angiogenesis inhibitor compound selected from the group consisting of 
       {(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester; 
       2-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester; 
       2-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-4-methyl-pentanoic acid methyl ester; 
       {(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-phenyl-acetic acid methyl ester; 
       (1-Carbamoyl-2-methyl-propyl)-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       (1-Carbamoyl-2-methyl-propyl)-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       (1-Hydroxymethyl-2-methyl-propyl)-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       2-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3,3-dimethyl-butyric acid methyl ester; 
       Cyclohexyl-2-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-acetic acid methyl ester; 
       2-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-pentanoic acid methyl ester; 
       [1-(1-Carbamoyl-2-hydroxy-ethylcarbamoyl)-2-methyl-propyl]-carbamic acid-(3R,4S, 5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl]-oxiranyl-1-oxa-spiro[2.5]oct-6-yl ester; 
       2-(3-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl}-ureido)-3-methyl-butyramide; 
       2-{(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid; 
       N-Carbamoyl (ID#31) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       N-Carbamoyl (ID#30) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       N-Carbamoyl (ID#32) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       N-Carbamoyl (ID#40) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       N-Carbamoyl (ID#39) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       N-Carbamoyl (ID#26) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       N-Carbamoyl (ID#27) (3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       (ID#24)-(2R-{(3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl}amino-3-methyl-butanol) ester; 
       (ID#36)-(2R-{(3R,4S,5S,6R) 5-methoxy-4-[(2R,3R) 2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl}amino-3-methyl-butanol) ester; 
       (ID#37)-(2R-{(3R,4S,5S,6R) 5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl}amino-3-methyl-butanol) ester; 
       (ID#38)-(2R-{(3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl}amino-3-methyl-butanol) ester; 
       (ID#34)-(2R-{(3R,4S,5S,6R)5-methoxy-4-[(2R,3R)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl}amino-3-methyl-butanol) ester; 
       {2-Methyl-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       [1-(2-Dimethylamino-ethylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       {1-[(2-Dimethylamino-ethyl)-methyl-carbamoyl]-2-methyl-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       [1-(3-Dimethylamino-propylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       [1-(3-Dimethylamino-2,2-dimethyl-propylcarbamoyl)-2-methyl-propyl]-carbamic acid 
       5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       [2-Methyl-1-(4-methyl-piperazine-1-carbonyl)-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       {2-Methyl-1-[2-(1-methyl-pyrrolidin-2-yl)-ethylcarbamoyl]-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; 
       [2-Methyl-1-(4-pyrrolidin-1-yl-piperidine-1-carbonyl)-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; and 
       [1-(4-Benzyl-piperazine-1-carbonyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester. 
     
     
         58 . A method of treating an angiogenic disease in a subject, comprising administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure 
       
         
           
           
               
               
           
         
       
       wherein
 A is a MetAP-2 inhibitory core; 
 W is O or NR; 
 each R is, independently, hydrogen or alkyl; 
 Z is —C(O)— or -alkylene-C(O)—; 
 P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is —OR, Q is not hydrogen; 
 or 
 Z is -alkylene-O— or -alkylene-N(R)—; 
 P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen; and a pharmaceutically acceptable salt thereof, thereby treating the angiogenic disease in the subject. 
 
     
     
         59 . The method of  claim 58 , wherein said angiogenic disease is an autoimmune disease. 
     
     
         60 . The method of  claim 59 , wherein said autoimmune disease is rheumatoid arthritis. 
     
     
         61 . The method of  claim 58 , wherein said angiogenic disease is cancer. 
     
     
         62 . The method of  claim 59 , wherein said autoimmune disease is selected from the group consisting of lupus erythematosus, psoriasis, multiple sclerosis, myasthenia gravis, vasculitis, and diabetes mellitus. 
     
     
         63 . The method of  claim 58 , wherein said angiogenic disease is a lymphoid malignancy. 
     
     
         64 . A method of treating an angiogenic disease in a subject, comprising administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure 
       
         
           
           
               
               
           
         
       
       wherein
 A is a Met-AP2 inhibitory core; 
 W is O or NR 2 ; 
 R 1  and R 2  are each, independently, hydrogen or alkyl; 
 X is alkylene or substituted alkylene; 
 n is 0 or 1; 
 R 3  and R 4  are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R 3  and R 4 , together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or R 3  and R 4  together form an alkylene group; 
 Z is —C(O)— or alkylene-C(O)—; and 
 P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group OR 5  or N(R 6 )R 7 , wherein
 R 5 , R 6  and R 7  are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or R 6  and R 7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring structure; 
 
 or 
 Z is —O—, —NR 8 —, alkylene-O— or alkylene-NR 8 —, where R 8  is hydrogen or alkyl; and 
 P is hydrogen, alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z. 
 
     
     
         65 . The method of  claim 64 , wherein said angiogenic disease is an autoimmune disease. 
     
     
         66 . The method of  claim 65 , wherein said autoimmune disease is rheumatoid arthritis. 
     
     
         67 . The method of  claim 64 , wherein said angiogenic disease is cancer. 
     
     
         68 . The method of  claim 65 , wherein said autoimmune disease is selected from the group consisting of lupus erythematosus, psoriasis, multiple sclerosis, myasthenia gravis, vasculitis, and diabetes mellitus. 
     
     
         69 . The method of  claim 64 , wherein said angiogenic disease is a lymphoid malignancy. 
     
     
         70 . A method of treating a parasitic infection in a subject, comprising administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure 
       
         
           
           
               
               
           
         
       
       wherein
 A is a MetAP-2 inhibitory core; 
 W is O or NR; 
 each R is, independently, hydrogen or alkyl; 
 Z is —C(O)— or -alkylene-C(O)—; 
 P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is —OR, Q is not hydrogen; 
 or 
 Z is -alkylene-O— or -alkylene-N(R)—; 
 P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen; and a pharmaceutically acceptable salt thereof, thereby treating the parasitic infection in the subject. 
 
     
     
         71 . The method of  claim 70 , wherein said parasitic infection is malaria. 
     
     
         72 . The method of  claim 70 , wherein said parasitic infection is Leishmaniasis. 
     
     
         73 . A method of treating a thymoma in a subject, comprising administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure 
       
         
           
           
               
               
           
         
       
       wherein
 A is a MetAP-2 inhibitory core; 
 W is O or NR; 
 each R is, independently, hydrogen or alkyl; 
 Z is —C(O)— or -alkylene-C(O)—; 
 P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is —OR, Q is not hydrogen; 
 or 
 Z is -alkylene-O— or -alkylene-N(R)—; 
 P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus; 
 Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen; and a pharmaceutically acceptable salt thereof, thereby treating the thymoma in the subject.